Expertise in
23
conditions

Dr. Salil Goorha

Hematology | Oncology
Laboratory Corporation Of America Holdings
80 Humphreys Center Dr Ste 330, 
Memphis, TN 
Accepting New Patients
Referral may be required
Expertise in
23
conditions
Laboratory Corporation Of America Holdings
80 Humphreys Center Dr Ste 330, 
Memphis, TN 

Overview

Salil Goorha is a Hematologist and an Oncologist practicing medicine in Memphis, Tennessee.

Dr. Goorha is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Childhood Acute Myeloid Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 9 peer reviewed articles and participating in 6 clinical trials. Dr. Goorha is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in MS

Hospital Affiliations

Baptist Memorial Hospital Tipton
Baptist Memorial Hospital Desoto
Baptist Memorial Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HMO Partners
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Magnolia Health
  • HMO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Laboratory Corporation of America Holdings
80 Humphreys Center Dr Ste 330, Memphis, TN 38120
Other Locations
Baptist Cancer Center-Memphis Malignant Hematology & Stem Cell Clinic
6027 Walnut Grove Rd Ste 206, Memphis,, TN 38120

Additional Areas of Focus

Dr. Goorha has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Mesna, Methotrexate, Ponatinib Hydrochloride, Prednisone, Vincristine Sulfate
Study Phase: Phase 3
A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)
A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2026
Intervention Type: Other
Study Phase: Not Applicable
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
The National Myelodysplastic Syndromes Natural History Study
The National Myelodysplastic Syndromes Natural History Study
Enrollment Status: Completed
Publish Date: February 03, 2026
Intervention Type: Other
A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
Enrollment Status: Completed
Publish Date: January 16, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Azacitidine, Cytarabine, Decitabine, Midostaurin, Nivolumab
Study Phase: Phase 2/Phase 3
Documentation and Delivery of Guideline-Consistent Treatment in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia (ALL)
Documentation and Delivery of Guideline-Consistent Treatment in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Completed
Publish Date: January 06, 2025
Intervention Type: Behavioral, Other
View 5 Less Clinical Trials

9 Total Publications

Experiences with real-world teclistamab administration in community and outpatient settings: a mixed-methods study of hematology providers.
Experiences with real-world teclistamab administration in community and outpatient settings: a mixed-methods study of hematology providers.
Journal: Current medical research and opinion
Published: February 18, 2026
Similar Doctors
Expertise in
17
conditions
Dr. Amar J. Gajjar
Hematology | Oncology
Expertise in
17
conditions
Dr. Amar J. Gajjar
Hematology | Oncology
Referral may be required

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
 (10.6 miles away)
901-595-2615
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Amar Gajjar is a Hematologist and an Oncologist practicing medicine in Memphis, Tennessee. Dr. Gajjar is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Posterior Fossa Tumor, Brain Tumor, Embryonal Tumor with Multilayered Rosettes, and Posterior Fossa Decompression. Dr. Gajjar is currently accepting new patients.

Expertise in
13
conditions
Dr. Giles W. Robinson
Hematology | Oncology
Expertise in
13
conditions
Dr. Giles W. Robinson
Hematology | Oncology
Referral may be required

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
 (10.6 miles away)
901-595-5175
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Giles Robinson is a Hematologist and an Oncologist practicing medicine in Memphis, Tennessee. Dr. Robinson is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Posterior Fossa Tumor, and Rhabdoid Tumor. Dr. Robinson is currently accepting new patients.

Expertise in
8
conditions
Dr. Jane S. Hankins
Hematology | Oncology
Expertise in
8
conditions
Dr. Jane S. Hankins
Hematology | Oncology
Referral may be required

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
 (10.6 miles away)
901-595-4153
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jane Hankins is a Hematologist and an Oncologist practicing medicine in Memphis, Tennessee. Dr. Hankins is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Splenectomy, and Adenoidectomy. Dr. Hankins is currently accepting new patients.

Frequently Asked Questions about Dr. Salil Goorha

How do I make an appointment with Dr. Salil Goorha?

You can book an appointment with Dr. Salil Goorha by calling their office at 901-752-6131. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Salil Goorha a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Salil Goorha is classified as an Distinguished expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Salil Goorha specialize in?

While Dr. Salil Goorha is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, and Childhood Acute Myeloid Leukemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Salil Goorha participate in research or clinical trials?

Yes. Dr. Salil Goorha has published 9 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Salil Goorha's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Salil Goorha accept my insurance?

Dr. Salil Goorha accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 901-752-6131 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Goorha's expertise for a condition
ConditionClose
    View All 20 Advanced Conditions
    View All 42 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile